Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis

M. Rabie Al-Turkmani, Steven D. Freedman, Michael Laposata

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Specific fatty acid alterations have been described in the blood and tissues of cystic fibrosis (CF) patients. The two most consistent alterations include decreased levels of linoleic acid (LA) and decreased levels of docosahexaenoic acid (DHA). Increased arachidonic acid (AA) release from membrane phospholipids, as well as changes in levels of AA and other monounsaturated and polyunsaturated fatty acids (PUFAs) have also been described in CF. Although mechanisms of fatty acid alterations have not yet been determined, these alterations may have an important role in the progression of the CF disease. There have been several clinical trials in which CF patients were supplemented with n-3 fatty acids. Most trials resulted in an increase in the levels of the supplemental fatty acids in the blood of CF patients in the absence of significant clinical improvement. It is recommended that future trials include a larger population of CF patients and measure multiple clinical outcomes.

Original languageEnglish (US)
Pages (from-to)309-318
Number of pages10
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume77
Issue number5-6
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Cystic Fibrosis
Fatty Acids
Arachidonic Acid
Blood
Monounsaturated Fatty Acids
Docosahexaenoic Acids
Linoleic Acid
Unsaturated Fatty Acids
Phospholipids
Tissue
Membranes
Clinical Trials
Population

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. / Al-Turkmani, M. Rabie; Freedman, Steven D.; Laposata, Michael.

In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 77, No. 5-6, 11.2007, p. 309-318.

Research output: Contribution to journalArticle

@article{61f760aeb4b24e95a399da4582cfb292,
title = "Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis",
abstract = "Specific fatty acid alterations have been described in the blood and tissues of cystic fibrosis (CF) patients. The two most consistent alterations include decreased levels of linoleic acid (LA) and decreased levels of docosahexaenoic acid (DHA). Increased arachidonic acid (AA) release from membrane phospholipids, as well as changes in levels of AA and other monounsaturated and polyunsaturated fatty acids (PUFAs) have also been described in CF. Although mechanisms of fatty acid alterations have not yet been determined, these alterations may have an important role in the progression of the CF disease. There have been several clinical trials in which CF patients were supplemented with n-3 fatty acids. Most trials resulted in an increase in the levels of the supplemental fatty acids in the blood of CF patients in the absence of significant clinical improvement. It is recommended that future trials include a larger population of CF patients and measure multiple clinical outcomes.",
author = "Al-Turkmani, {M. Rabie} and Freedman, {Steven D.} and Michael Laposata",
year = "2007",
month = "11",
doi = "10.1016/j.plefa.2007.10.009",
language = "English (US)",
volume = "77",
pages = "309--318",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",
number = "5-6",

}

TY - JOUR

T1 - Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis

AU - Al-Turkmani, M. Rabie

AU - Freedman, Steven D.

AU - Laposata, Michael

PY - 2007/11

Y1 - 2007/11

N2 - Specific fatty acid alterations have been described in the blood and tissues of cystic fibrosis (CF) patients. The two most consistent alterations include decreased levels of linoleic acid (LA) and decreased levels of docosahexaenoic acid (DHA). Increased arachidonic acid (AA) release from membrane phospholipids, as well as changes in levels of AA and other monounsaturated and polyunsaturated fatty acids (PUFAs) have also been described in CF. Although mechanisms of fatty acid alterations have not yet been determined, these alterations may have an important role in the progression of the CF disease. There have been several clinical trials in which CF patients were supplemented with n-3 fatty acids. Most trials resulted in an increase in the levels of the supplemental fatty acids in the blood of CF patients in the absence of significant clinical improvement. It is recommended that future trials include a larger population of CF patients and measure multiple clinical outcomes.

AB - Specific fatty acid alterations have been described in the blood and tissues of cystic fibrosis (CF) patients. The two most consistent alterations include decreased levels of linoleic acid (LA) and decreased levels of docosahexaenoic acid (DHA). Increased arachidonic acid (AA) release from membrane phospholipids, as well as changes in levels of AA and other monounsaturated and polyunsaturated fatty acids (PUFAs) have also been described in CF. Although mechanisms of fatty acid alterations have not yet been determined, these alterations may have an important role in the progression of the CF disease. There have been several clinical trials in which CF patients were supplemented with n-3 fatty acids. Most trials resulted in an increase in the levels of the supplemental fatty acids in the blood of CF patients in the absence of significant clinical improvement. It is recommended that future trials include a larger population of CF patients and measure multiple clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=36649003127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36649003127&partnerID=8YFLogxK

U2 - 10.1016/j.plefa.2007.10.009

DO - 10.1016/j.plefa.2007.10.009

M3 - Article

VL - 77

SP - 309

EP - 318

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

IS - 5-6

ER -